The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors

Tumour markers have no established role in the monitoring of the course of metastatic breast cancer during antineoplastic therapy, yet cancer antigen 15.3 (CA15.3) and carcinoembryonic antigen (CEA) are commonly used in clinical practice to aid in the early detection of progression of disease (PD)....

Full description

Bibliographic Details
Main Authors: Federico Sottotetti, Elisa Ferraris, Barbara Tagliaferri, Raffaella Palumbo, Erica Quaquarini, Cristina Teragni, Emanuela Balletti, Claudia Leli, Andrea Premoli, Ludovica Mollica, Silvia Puglisi, Silvia Sardi, Alberto Malovini, Paolo Pedrazzoli, Antonio Bernardo
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2022-09-01
Series:Drugs in Context
Subjects:
breast cancer
cdk4/6 inhibitors
tumour markers
Online Access:https://www.drugsincontext.com/the-prognostic-role-of-variations-in-tumour-markers-cea-ca15-3-in-patients-with-metastatic-breast-cancer-treated-with-cdk4-6-inhibitors

Internet

https://www.drugsincontext.com/the-prognostic-role-of-variations-in-tumour-markers-cea-ca15-3-in-patients-with-metastatic-breast-cancer-treated-with-cdk4-6-inhibitors

Similar Items